drugset / Trial / NCT00554970
A Study of 2 Doses of MAP0010 in Adult Asthmatics
Phase 2
Completed
32 enrolled
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan · collab
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days.
Timeline
- Start
- 2007-11
- Primary completion
- 2008-01
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | 0.25 mg | Other |
| Subject | Budesonide | Small molecule | 0.5 mg | Other |
| Subject | Budesonide | Small molecule | — | Other |